Neuroscience Start-up Bexorg Secures $42.5 Million
Neuroscience start-up Bexorg has raised $42.5 million in series A funding to develop new drug targets using donated human brains and artificial intelligence.
The company, led by CEO and co-founder Zvonimir Vrselja, aims to address the challenges in developing drugs for neurodegenerative diseases.
Most drug candidates developed for the central nervous system never make it to regulatory approval, falling into what’s termed the valley of death.
According to Vrselja, the issue lies in the fact that previous discoveries were made in
simplified model systems—from cell cultures, organoids, rather than actual human brains.
- Bexorg trains AI programs on donated human brains
- Aims to develop new biomarkers and targets for neurodegenerative diseases
Author's summary: Bexorg raises $42.5 million to develop AI-driven neurodegenerative disease treatments.